The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study

IntroductionThe clinical relevance of soluble forms of programmed cell death-1 (sPD-1) and programmed cell death-ligand 1 (sPD-L1) remains unclear. We here investigated the relation between the efficacy of PD-1 blockade and pretreatment plasma levels of sPD-1 and sPD-L1 across a broad range of cance...

Full description

Bibliographic Details
Published in:	Frontiers in Immunology
Main Authors:	Takashi Kurosaki, Kenji Chamoto, Shinichiro Suzuki, Hiroaki Kanemura, Seiichiro Mitani, Kaoru Tanaka, Hisato Kawakami, Yo Kishimoto, Yasuharu Haku, Katsuhiro Ito, Toshiyuki Sato, Chihiro Suminaka, Mami Yamaki, Yasutaka Chiba, Tomonori Yaguchi, Koichi Omori, Takashi Kobayashi, Kazuhiko Nakagawa, Tasuku Honjo, Hidetoshi Hayashi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-12-01
Subjects:	immune checkpoint inhibitor nivolumab pembrolizumab soluble PD-1 soluble PD-L1
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1325462/full

Similar Items

Sex difference in the expression of PD-1 of non-small cell lung cancer
by: Yong Gu, et al.
Published: (2022-10-01)

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy
by: Junko Tanizaki, MD, PhD, et al.
Published: (2023-12-01)

Prognostic significance of soluble PD-L1 in prostate cancer
by: Margarita Zvirble, et al.
Published: (2024-07-01)

Genetic Co-Administration of Soluble PD-1 Ectodomains Modifies Immune Responses against Influenza A Virus Induced by DNA Vaccination
by: Pierre Tannig, et al.
Published: (2020-10-01)

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease
by: Ayaka Hayashi, et al.
Published: (2025-01-01)

Analysis of the mechanisms regulating soluble PD-1 production and function in human NK cells
by: Francesca Romana Mariotti, et al.
Published: (2023-08-01)

Soluble PD-L1: From Immune Evasion to Cancer Therapy
by: Denisa Dragu, et al.
Published: (2025-04-01)

Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis
by: Takashi Shimizu, et al.
Published: (2023-11-01)

Corrigendum: Soluble PD−L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis
by: Takashi Shimizu, et al.
Published: (2023-12-01)

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice
by: Shanshan (Jenny) Zhong, et al.
Published: (2024-07-01)

Secreted AZGP1 induced by 5-FU binds to PD-L1 and promotes apoptosis in cholangiocarcinoma
by: Ji-Eun You, et al.
Published: (2025-09-01)

Characteristics of PD‐1+CD4+ T cells in peripheral blood and synovium of rheumatoid arthritis patients
by: Yan‐juan Chen, et al.
Published: (2024-01-01)

An investigation of the relationship between sPD-1, sPD-L1 and severe pneumonia patients admitted to ICU and its clinical significance
by: Zirong Gao, et al.
Published: (2025-06-01)

Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients
by: Takeru Kashiwada, et al.
Published: (2024-05-01)

The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer
by: Weifang Shao, et al.
Published: (2022-08-01)

Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)
by: Adrien Costantini, et al.
Published: (2025-08-01)

Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
by: Alok Kumar, et al.
Published: (2020-03-01)

Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer
by: Fumihiko Ando, et al.
Published: (2024-05-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
by: Kimberly Krueger, et al.
Published: (2022-09-01)

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
by: Kimberly Krueger, et al.
Published: (2022-10-01)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
by: Liudmila Spirina, et al.
Published: (2021-09-01)

Molecular dynamics insights into the redox effects on PD-1/PD-L1 and PD-1/PD-L2 interactions
by: Rasulbek Mashalov, et al.
Published: (2025-09-01)

Role of regulation of PD-1 and PD-L1 expression in sepsis
by: Teng Zhang, et al.
Published: (2023-03-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

PD-1, PD-L1, and PD-L2 Expression as Predictive Markers in Rare Feline Mammary Tumors
by: Maria Franco, et al.
Published: (2025-08-01)

نقش PD-1/ PD-L1 و Anti-PD-1/ PD-L1 در پیشرفت و سرکوب سرطان
by: نرگس عبدالهی, et al.
Published: (2023-11-01)

Regulatory mechanisms of PD-1/PD-L1 in cancers
by: Xin Lin, et al.
Published: (2024-05-01)

Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes
by: Xingcheng Yang, et al.
Published: (2024-10-01)

Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression
by: Chang-cheng Ren, et al.
Published: (2023-12-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020-06-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

PD-L1/PD-1 pathway: a potential neuroimmune target for pain relief
by: Daling Deng, et al.
Published: (2024-04-01)

Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy
by: Terufumi Kubo, et al.
Published: (2021-07-01)

Association of PD-1 and PD-L1 protein expression with selected clinical and morphological parameters in colorectal cancers
by: Paulina Poter, et al.
Published: (2024-05-01)

Higher serum sPD-L1 levels after radiotherapy indicate poor outcome in hepatocellular carcinoma patients
by: Yang Zhang, et al.
Published: (2022-12-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
by: Faisal K. Alkholifi, et al.
Published: (2022-11-01)